Nicolas Gilles has completed his PhD at Paris Descartes University. He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class. His strongest expertise lies in Receptor Pharmacology, Synthetic Production of Disulfide-Linked Animal Toxins and in vivo experiments. He has published more than 70 papers and three patents. His strongest interest is now to stimulate the therapeutic development of animal toxins for the benefit of human health. Nicolas Gilles has completed his PhD at Paris Descartes University. He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class. His strongest expertise lies in Receptor Pharmacology, Synthetic Production of Disulfide-Linked Animal Toxins and in vivo experiments. He has published more than 70 papers and three patents. His strongest interest is now to stimulate the therapeutic development of animal toxins for the benefit of human health.
Nephrology